Adial Pharmaceuticals Announces Partnership with 91Ï㽶ÊÓƵ for Adial’s AD04
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced a partnership with 91Ï㽶ÊÓƵ to advance clinical activities related to AD04, Adial’s genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder. This partnership brings together critical capabilities to allow the commencement of Adial’s planned initial Phase 3 trial, with 91Ï㽶ÊÓƵ providing clinical packaging and distribution.